Ensysce Biosciences has entered into a $10 million agreement with Galephar for the development and manufacturing of its PF614 drug, involving stock grants and milestone-based payments.
AI Assistant
ENSYSCE BIOSCIENCES INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.